|Bid||12.15 x 1100|
|Ask||0.00 x 4000|
|Day's Range||17.20 - 17.63|
|52 Week Range||12.89 - 19.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.17|
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotechnology company, today announced that the company in collaboration with researchers will present clinical data for IW-3718 during Digestive Disease Week (DDW) in Washington D.C., June 2 through June 5, 2018. One of the abstracts will be presented at the Distinguished Abstract Plenary Session. During this session, Michael Vaezi, Ph.D., M.D., of Vanderbilt University will share Phase IIb data on the effect of IW-3718 on heartburn and regurgitation – the two most frequent and bothersome symptoms of gastroesophageal reflux disease (GERD)1 – in patients with persistent GERD despite treatment with proton pump inhibitors (PPIs).
Ironwood Pharmaceuticals Inc. activist investor Alex Denner helped send shares higher by almost a third since announcing his intention last month to join the board. The drugmaker is less than two weeks from its highly anticipated annual meeting and Sarissa Capital Management has yet to file a final proxy soliciting shareholder votes for Denner’s nomination. "My sense of it is: A lot is going on behind the scenes," Berenberg’s Patrick Trucchio said, adding that the delay "seems odd." The agency representing Sarissa, D.F. King & Co., expects a definitive proxy to be filed, writes Trucchio, who has a buy rating on the stock and a Street-high price target.
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced that it has mailed a letter to shareholders highlighting the experience and personal perspectives of the company’s director nominees: Lawrence Olanoff, M.D., Ph.D., Amy Schulman and Douglas Williams, Ph.D. The Ironwood Board of Directors strongly recommends that shareholders vote on the WHITE proxy card “FOR” Ironwood’s experienced, diverse and independent nominees. Ironwood’s letter to shareholders and other materials regarding the Board’s recommendation for the 2018 Annual Meeting can be found at www.ironwoodannualmeeting.com.
NEW YORK, NY / ACCESSWIRE / May 10, 2018 / U.S. markets spiked Wednesday as strong performances by the energy, financials and technology sectors lifted the major indexes higher. The Dow Jones Industrial ...
Commercial stage biopharma company Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD )'s Linzess, which it markets along with Allergan plc (NYSE: AGN ) in the U.S., is a major revenue earner for the company. ...
Ironwood Pharmaceuticals, Inc.(IRWD), a commercial biotech company, today announced that it filed an investor presentation with the Securities and Exchange Commission in connection with the company’s Annual Meeting of Shareholders scheduled for May 31, 2018.
NEW YORK, May 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CASI ...
Ironwood Pharmaceuticals, Inc. (IRWD) and Allergan plc (AGN) announced today that the companies have reached an agreement with Aurobindo Pharma Ltd., resolving patent litigation brought in response to Aurobindo Pharma’s abbreviated new drug application (ANDA) seeking approval to market a generic version of LINZESS (linaclotide) prior to the expiration of the companies’ applicable patents. The settlement with Aurobindo is the second patent infringement settlement the companies have reached with respect to LINZESS.
LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on Ironwood Pharma, Inc. (IRWD). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=IRWD as the Company's latest news hit the wire. On May 01, 2018, the Company declared that its Board of Directors has approved an intent to separate into two independent, publicly-traded Companies, i.e.
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.
Alex Denner, a protege of Carl Icahn, is known for orchestrating sales of companies in which he invests — including some local biotechs.
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced that it filed definitive proxy materials with the Securities and Exchange Commission in connection with Ironwood’s Annual Meeting of Shareholders on May 31, 2018. Ironwood shareholders of record as of the close of business on April 6, 2018 will be entitled to vote at the Annual Meeting. The Ironwood Board of Directors strongly recommends that shareholders vote on the WHITE proxy card “FOR” Ironwood’s experienced, diverse and independent nominees: Lawrence Olanoff, M.D., Ph.D., Amy Schulman and Douglas Williams, Ph.D.
It will leave Ironwood as a traditional drugmaker focused on selling medications for irritable bowel syndrome, gout and reflux disease, with the goal of earning regular profits from the revenue growth. The other company will be more akin to a biotech aiming to bring to market promising but unproven drugs for rare disorders, such as sickle cell disease.
-- AboutYourGut.com Provides Resources and Education Focused on Irritable Bowel Syndrome with Diarrhea (IBS-D), Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) ...
Ironwood Pharmaceuticals plans to separate into two entities next year. Activist investor Alex Denner of Sarissa Capital has invested in the company and is seeking a seat on its board. Ironwood Pharmaceuticals' IRWD stock rose Tuesday after the company said it plans to separate next year, immediately establishing profitability for its commercial entity and separating some of its pipeline assets into another unit.
The Cambridge, Massachusetts-based company said it had a loss of 29 cents per share. Losses, adjusted for one-time gains and costs, came to 27 cents per share. The drugmaker posted revenue of $69.2 million ...
The 730-employee company said that both businesses would be publicly traded and headquartered in Cambridge.
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced that its Board of Directors has authorized an intent to separate into two independent, publicly traded companies (Ironwood and “R&D Co.”). The separation is expected to be completed in the first half of 2019 and is anticipated to be tax-free to Ironwood shareholders. Following the separation, Ironwood anticipates being a profitable company, building on its commercial success to-date to accelerate growth of its in-market products and advance development programs targeting treatments for gastrointestinal (GI) diseases, uncontrolled gout, and abdominal pain.
Ironwood Pharmaceuticals, Inc. , a commercial biotechnology company, today provided an update on its first quarter 2018 results and recent business activities.
Ironwood Pharmaceuticals, Inc. today announced it will host its first quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, May 1, 2018.
Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The net inflows of $122 million over the last one-month into ETFs that hold IRWD are among the lowest of the last year and appear to be slowing.
Ironwood Pharmaceuticals told shareholders Monday that it's learned biotech activist investor Alex Denner of Sarissa Capital is seeking to join its board.
Ironwood Pharmaceuticals, Inc. , a commercial biotech company, today announced that it has received notice from Sarissa Capital Management LP that it intends to nominate its chief investment officer Alex Denner to stand for election to the Ironwood Board of Directors at Ironwood’s 2018 Annual Meeting of Shareholders.